ASCO GUIDELINES Bundle

Multiple Myeloma Treatment

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475482

Contents of this Issue

Navigation

Page 6 of 15

7 ➤ Assessment of other risk factors such as renal insufficiency, age, presence of plasma cell leukemia, circulating plasma cells, extramedullary disease and frailty, should also be considered/ performed. (Strong Recommendation; EB-H-B) ➤ In patients with genetic high-risk disease a triplet combination of proteasome inhibitor, immunomodulatory drug and a steroid should be the initial treatment, followed by one or two autologous SCT, followed by a proteasome inhibitor-based maintenance until progression. (Strong Recommendation; EB-H-B) ➤ In patients with renal insufficiency, drugs should be modified based on renal clearance. (Strong Recommendation; EB-H-B) ➤ In patients with plasma cell leukemia or extra medullary disease, cytotoxic chemotherapy may have a role. (Moderate Recommendation; EB-I-B) ➤ The IMWG revised response criteria should be used for response assessment. (Strong Recommendation; EB-H-B) ➤ All measurable parameters need to be followed including light and heavy chain analysis. (Strong Recommendation; EB-H-B) ➤ All responses excluding marrow and imaging should be confirmed as per IMWG criteria. (Strong Recommendation; EB-H-B) ➤ Response assessment should be performed after one cycle of therapy, and once a response trend is observed it may be done every other cycle and less frequently once patient is in a plateau. (Strong Recommendation; EB-H-B)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Multiple Myeloma Treatment